Essential Questions to ask if you or a loved one has been diagnosed with Mesothelioma ***IMPORTANT***

Survival Information at Cytoreductive Surgery combined with HIPEC

Posted on: October 14, 2023 *Updated on: May 27, 2024

Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has demonstrated promising results for patients with peritoneal mesothelioma. Let’s break down the provided survival rates:

  1. National Cancer Database on Cytoreduction with HIPEC:
    • For patients who underwent the procedure: The average survival was 38 months (or 3 years and 2 months). This is a considerable improvement compared to historical data.
    • For patients who did not undergo the procedure: The survival was significantly shorter at an average of 7.1 months. This stark contrast demonstrates the potential benefit of the procedure for appropriate candidates.
  2. Wake Forest Baptist Cancer Center:
    • They reported a slightly higher median survival of 40 months (or 3 years and 4 months) for patients undergoing the combined procedure. It’s worth noting that “median survival” means that half of the patients survived longer than this time, and half survived less.
    • Their reported five-year survival rate was around 30%. This means that 30% of the patients who underwent the procedure were still alive five years post-treatment.
  3. Reports from other centers:
    • Some centers have even more optimistic results, with five-year survival rates reported to be around 50%. The variability between centers can be due to numerous factors such as patient selection, surgical techniques, and postoperative care.

From the information provided, a few key takeaways emerge:

  • The combination of cytoreductive surgery and HIPEC offers a significant improvement in survival for patients with peritoneal mesothelioma compared to those who do not undergo the procedure.
  • The variability in survival rates among different treatment centers underscores the importance of experience, expertise, and continuous research in this area.
  • While the treatment has shown promise, it’s crucial for patients to discuss with their medical team to understand if they are suitable candidates, given the complexities and potential complications of the procedure.